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A STUDY OF PHOTOSENSITIVITY OCCURRING WITH
CHLORPROMAZINE THERAPY*
JOHN H. EPSTEIN, M.D.t, LOUIS A. BRUNSTING, M.D.t, MAGNUS C.
PETERSEN, M.D4, AND BERT E. SCHWARZ, M.D4
In 1900, Prime (1) noted that certain patients developed unusual cutaneous
reactions to the sun's rays while under eosin therapy for epilepsy. Since that
time, many therapeutic agents have been found to produce photosensitivity.
Recently chlorpromazine, a relatively new tranquilizing medication, now in
wide clinical use, has been noted to cause sun-sensitivity reactions. It is the
purpose of this project to determine the incidence and, if possible, the nature of
the photosensitivity produced by this drug.
PROCEDUEE
A. The Study of the Effect of Chiorpromazine Therapy on the Skin-erythema Re-
sponse to a "B" Carbon-arc Exposure
1. Method .—The subjects consisted of 72 patients from the Rochester (Minne-
sota) State Hospital who were suffering from a variety of mental disorders, the
majority being schizophrenics. An equal number of males and females was
selected.
The patients were divided into two groups:
a. Group A consisted of 58 patients (30 male and 28 female) with no history
of previous chiorpromazine intake, or no known reaction to the drug if they had
taken it.
b. Group B consisted of 14 patients (six male and eight female) with histories
of possible previous cutaneous reactions to chlorpromazine. The eruption in two
of these cases appeared to have been induced by exposure to the sun.
In the process of testing, each patient was given an average "minimal erythema
dose" to an area on the back measuring 3 inches by 3 inches. The dose consisted
of a 4-minute exposure at a distance of 24 inches from a "B" carbon-arc source.Ij
In addition, a comparable site was exposed for 5 minutes, from the same distance,
through a "7740" Corning glass filter. This filter absorbs almost all the effective
erythemogenic ultraviolet rays shorter than 3,100 A.
* Presented at the Seventeenth Annual Meeting of The Society for Investigative Der-
matology, Inc., Chicago, Illinois, June 10, 1956.
Abridgment of thesis submitted by Dr. Epstein to the Faculty of the Graduate School
of the University of Minnesota in partial fulfillment of the requirements for the degree of
Master of Science in Dermatology.
t From the Section of Dermatology, Mayo Clinic and the Mayo Foundation, Rochester,
Minnesota.
The Mayo Foundation, Rochester, Minnesota, is a part of the Graduate School of the
University of Minnesota.
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The patients in group A were given preliminary tests as outlined in the pre-
ceding paragraph. The exposed areas were observed immediately, at hour, at
6 hours, and daily for 1 week. Then 100 mg. of chiorpromazine was administered
orally, twice daily for 14 days. After the first week of therapy, the tests were
repeated in previously unexposed areas. Observations were made, as before, for
a week or more when necessary.
The same procedure was utilized for group B; however, some of these patients
were taking chiorpromazine at the time of the first test and the method was
altered to accommodate for this factor. The dosage in this group varied from
100 to 600 mg. per day.
2. Results.—Utilizing the scale shown in table 1 the results on each of the pa-
tients were recorded. The erythema and edema occurring at the immediate and
3-hour readings appeared to be heat responses and were disregarded as evidence
of photosensitivity. In comparing the individual reactions during each testing
period only a marked degree of difference was held to be of significance, owing
to the subjective nature of the interpretation. A difference of 2 grades of ery-
thema, edema on 2 or more days, or both, were felt to be indicative of an in-
creased sensitivity to the "B" carbon exposure (in comparing the reactions of
the patients on and off medication).
Using the foregoing criteria, eight patients (two female and six male) from
group A showed abnormal reactions to the "B" carbon exposures while taking
chiorpromazine. These reactions appeared to be exaggerations of the normal
sunburn response. In addition, patient 15 (female) showed a significantly pro-
longed reaction to the carbon-arc exposure and an abnormal response to direct
sunlight while taking chiorpromazine. She is included as a reactor. One other
patient (case 27) showed an exaggerated reaction to the test exposure only while
not being treated with the drug.
Seven of the patients in group A developed maculopapular, somewhat urti-
canal eruptions while taking the drug. The trunk, shoulders, upper extremities,
face, and neck were involved primarily, although one patient (case 24) had a
generalized reaction. The eruptions appeared between the seventh and the four-
teenth day of therapy and lasted 5 to 31 days. In one instance the eruption
cleared before the drug was discontinued. Two of the subjects (cases 1 and 15)
showed a marked accentuation of the lesions over the exposed parts. They had
received an undetermined amount of direct sunlight to these areas prior to the
onset of the eruptions. The other five subjects had not been in the sun and did
not show this definite pattern. Three of these seven patients, including cases 1
and 15, showed abnormal reactions at the test sites to the "B" carbon exposures.
One patient in group B showed an increased response to the carbon-arc ex-
posure oniy while not taking the medication. No other abnormal reactions were
noted in this group.
No reactions other than those attributed to heat occurred in any of the pa-
tients when the erythemogenic ultraviolet rays were absorbed by the "7740"
Corning glass filter.
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Fm. 1. Absorption spectrum of chiorpromazine.
B. Qualitative Urinary Porphyrin Studies.
1. Method.—The subjects consisted of six patients from group A and 13 pa-
tients from group B. Three of the patients from group A were those who had
shown the most intense reactions to the carbon-arc exposure while taking chior-
promazine (cases 1, 15, and 24).
Fresh urine specimens were collected, once while the subjects were under
therapy, and again 1 week after the drug had been discontinued. Tests for
uroporphyrin, coproporphyrin, and porphobilinogen were made.
2. Results.—The examinations for uroporphyrin were negative in all cases.
Small amounts of coproporphyrin were found in three instances, but only while
the patients were not taking the drug.
Weakly positive reactions for porphobilinogen were noted in the specimens
from 13 of the subjects. In nine patients (including cases 1, 15, and 24) these
reactions were found regardless of chiorpromazine intake. In two instances the
tests were positive only while the patients were taking the drug, and in two
others, only after cessation of therapy.
C. Studies on the Absorption Spectrum of Chiorpromazine
1. Method.—A 1 per cent aqueous solution of chlorpromazine was prepared
by dissolving 100 mg. of powdered chlorpromazine hydrochloride in 10 cc. of
distilled water. * The absorption spectrum was then determined, utilizing the
Beckman Model D.U. Spectrophotometer.
* All drugs used in the study were supplied free of charge by Smith, Kline &French
Laboratories.
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. Results.—Figure 1 shows that the solution completely absorbed the ultra-
violet rays between 2,000 A. and 3,700 A. However, there was almost complete
transmission of the longer wave lengths from 4,200 A. up to at least 8,000 A.
(this was as far as the determinations were carried).
COMMENT
A. The Incidence of Photosensitization Produced by Chiorpromazine Therapy
An attempt has been made to determine the incidence of photosensitivity pro-
duced by chiorpromazine therapy. We found that nine of the 72 patients studied
showed exaggerated responses to the "B" carbon-arc exposure while taking the
medication. None of these nine patients had had any previous reactions to the
drug. Since two patients developed increased reactions while not taking the drug,
we were unable to determine definitely the incidence of photosensitivity induced
by chiorpromazine. However, it appears that at least a small percentage of pa-
tients treated with chlorpromazine will become abnormally sensitive to certain
wave lengths in the sun's spectrum.
No reactions, other than those occurring at the immediate and -hour read-
ings, were noted when the ultraviolet rays shorter than 3,100 A. were absorbed
by the "7740" Corning glass filter. The early changes noted were regarded as
being most likely due to heat. The erythema was transient, and no residual pig-
mentation was noted. There was no relation to chlorpromazine therapy. It was
concluded that the abnormal reactions noted in our study were produced by
wave lengths shorter than 3,100 A. This corresponds to the zone of the spectrum
absorbed by a 1 per cent solution of chlorpromazine.
B. The Relationship of Porphyrin Metabolism to Chiorpromazine-induced Photo-
sensitivity
The relationship of certain photosensitive states, as well as some forms of he-
patic dysfunction, to abnormalities of porphyrin metabolism, in man and in
animals, is well known (2). It seemed reasonable to consider that such abnor-
malities might possibly be involved in the development of reactions associated
with the administration of chiorpromazine.
In the first place, none of the patients in this series exhibited clinical evidence
of porphyria or of gross impairment of hepatic function. Samples of fresh urine
from 19 patients, including members of both groups, were examined for por-
phyrins. Three specimens were slightly fluorescent, owing to the presence of
small amounts of coproporphyrin. Reactions for uroporphyrin were invariably
negative. In 13 patients, reactions for porphobilinogen were weakly positive on
occasions, both during therapy and after chiorpromazine was discontinued. The
significance of these findings is not clear; no relationship to light sensitivity could
be established.
C. The Possible Mechanism of Chlorpromazine-induced Photosensitization
Since chlorpromazine is closely related to phenothiazine and phenergan (fig.
2), the production of photosensitivity by this drug is not altogether unexpected,
phenothiazine and phenergan being well-known photosensitizers. However, the
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FIG. 2. Relation of chemical structure of chiorpromazine to those of phenothiazine and
phenergan.
mechanism for the abnormal reactions to the sun induced by these substances
has not been definitely determined.
DeEds and his co-workers (3) noted that leukothionol and thionol are urinary
excretory products of phenothiazine. Because of the relationship between thionol,
thionine, and methylene blue (fig. 3), these authors postulated that a leukothio-
nol-thionol system might be responsible for the photosensitivity reactions pro-
duced by phenothiazine. Methylene blue and other thiazine dyes, including
thionol, have known photodynamic properties (4). DeEds and co-workers did
not determine the offending wave lengths in their studies.
Recently Cohen and Nash (5) suggested that the 2-chloro-leukothionol—2-
chiorothionol system might be responsible for chlorpromazine-induced photo-
sensitivity responses. However, the formation of these products during chior-
promazine therapy has yet to be proved. In addition, the abnormal reactions
noted in our study appeared to be exaggerations of the normal sunburn response
and were dependent on the ultraviolet wave lengths shorter than 3,100 A.
Blum (6) has stated that these short ultraviolet rays are not likely to be involved
in photodynamic reactions. However, since the absorption spectrum of chior-
promazine includes these short "erythemogenic" rays, the drug could act as a
light absorber for some photochemical reaction (probably not photodynamic in
nature). This would require a permeation of the drug into the epidermis.
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On the other hand, chlorpromazine or its transformation products might act
directly on the epidermal cells. Such a direct effect would also necessitate that
the drug, or its metabolic products, reach the epidermis. The actual distribution
of chiorpromazine in humans has not been determined. Animal and human
studies have shown that the drug is readily absorbed after oral, rectal or paren-
teral administration. Although it disappears rapidly from the blood stream, only
small amounts appear in the urine in the first 24 hours (7). These findings sug-
gest that the drug is either rapidly metabolized or deposited in the tissues.
Recently Berti and Cima (8-10), working with laboratory animals, found that
the concentration of chiorpromazine, in various organs, increased progressively
for 48 hours after a single injection of the drug. Unfortunately, the only skin
concentration studies were done on fragments of skin from the sites of the in-
jections. Therefore, at present, it is not known if chiorpromazine or its transfor-
mation products reach the epidermal cells.
Another possible mechanism for this exaggerated sunburn reaction may be
related to the potent effect of chlorpromazine on blood vessels. The drug appears
to cause vasodilatation through both central and peripheral actions (11). Since
the erythema noted in the normal sunburn response is due to dilatation of the
dermal blood vessels, a substance which tends to enhance this vasodilatation
might cause an exaggerated response. It is possible that such a mechanism at
least contributes to the chiorpromazine-induced photosensitivity reactions. Ob-
viously this would not necessitate permeation of the epidermis by the drug.
fl1Lci
Leukothionol Thionol
H2N' NH
HCI
N(CH3)2 [ci]
Fm. 3. Relation of chemical structures of thionol, thionine and methylene blue, and of
their leuko derivatives.
Leukothionin Thionin
HCI
Leukomethylene blue Methylene blue
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D. Drug Eruptions Unrelated to the Carbon-arc Exposure
Maculopapular, somewhat urticarial eruptions, chiefly over the trunk, shoul-
ders, upper extremities, face, and neck, were noted in seven of the 72 patients
while they were under chiorpromazine therapy. These reactions were unrelated
to the carbon-arc testing procedure, but in two instances direct sun exposure to
limited areas appeared to precipitate the eruptions. These two patients also
showed markedly exaggerated responses to the carbon-arc exposures at the test
sites while on the drug.
The incidence of drug eruptions (9.7 per cent) in our series is similar to that
noted by other authors (12—14). Also, the maculopapular, urticarial type of
reaction has been reported most frequently, though scarlatiniform, morbihiform,
exfoliative, and even erythema multiforme-like eruptions have been noted (7).
Recently Margolis and his co-workers (15) observed a case in which the chior-
promazine-induced dermatitis cleared before the drug was stopped. Interestingly
enough, the eruption in one of our cases also disappeared while the patient was
still under therapy.
SUMMARY
1. Nine of 72 patients under chlorpromazine therapy developed abnormal re-
actions in test sites to ultraviolet rays in the spectral zone below 3,100 A. These
reactions appeared to be exaggerations of the normal sunburn response.
2. A 1 per cent solution of chiorpromazine hydrochloride, examined spectro-
photometrically, showed complete absorption of the wave lengths between 2,000
and 3,700 A. Thus the absorption pattern of the drug included the ultraviolet
rays shorter than 3,100 A.
3. Examinations of the urine of 19 of the patients revealed no abnormal por-
phyrins. The presence of weakly positive reactions for porphobilinogen in certain
specimens is unexplained. None of the subjects showed clinical evidence of he-
patic dysfunction or porphyria.
4. Several possible mechanisms of the production of photosensitivity by chlor-
promazine have been discussed.
5. Dermatitis medicamentosa of a maculopapular, urticarial type occurred in
approximately 10 per cent of the subjects. In two instances these reactions were
apparently precipitated by exposure to natural sunlight.
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DISCUSSION
DR. MILTON M. CAHN, (Philadelphia, Pa.): I want to congratulate Dr. Ep-
stein and his associates for this important piece of work. There are millions of
people taking these drugs and the experimental work done by Dr. Epstein bears
out our clinical work. (Cahn, M. M. & Levy, E. J.: Ultraviolet Light Factor in
Chiorpromazine Dermatitis. Arch Dermat. In Press). These drugs are related
chemically to the sulfa group, and other drugs which have been known, in some
instances, to cause agranulocytosis and blood dyscrasias. In 1955 we studied 105
patients who had been taking Chlorpromazine. Many of them had been taking
the drug for almost two years, and five developed photosensitivity reactions,
manifested by eruptions which came on two to eight hours after exposure to
summer sunlight. This slide shows (demonstrating) why you cannot reproduce
an eruption using the hot quartz mercury arc lamp. The mercury arc emits a
line type of spectrum and does not contain intense emissions between 2967 A
and 3025 A—the area responsible for the eruption. Dr. Epstein used a carbon
arc source—a continuous spectrum—with rays between 2967 A and 3025 A, and
the patients developed an eruption. The eruption, therefore, will only occur when
there are rays of this type, as in the summertime, and patients will not develop
this type of an eruption from winter sunlight which does not contain rays below
3025 A. The eruption, when it does occur after exposure to summer sunlight, is
only transient and does not necessitate withdrawal of the drug, providing the
patient avoids exposure.
DR. STEPHEN ROTHMAN, (Chicago, Ill.): The wavelengths 2967 and 3022 are
well represented in the linear emission spectrum of the mercury arc. Thus, I do
not understand why these effects could not be shown by using mercury lamps.
DR. THEODORE CORNBLEET, (Chicago, Ill.): Chlorpromazine does not produce
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more reactions in dermatologic patients than in others. The number showing
changes as a result of light sensitivity is surprisingly small, considering chior-
promazine's photodynamic reactive properties. Dr. Bluefarb tried to utilize the
latter in psoriasis, but the experiment was unfortunately a failure. This is some-
what surprising, because the emission spectrum of chlorpromazine has certain
similarities to that of coal tar, though there are some differences. It seems one
may expect any substance with photodynamic properties to produce light sensi-
tivity in some people. Chiorpromazine is one such drug in this group.
DR. ROBERT STOLAR, (Washington, D. C.): I would like to add one observa-
tion on patients with psoriasis who were taking this drug. Three patients de-
veloped marked erythema on the exposed areas: the V of the neck, the face and
ears and the forearms. In addition to antipsoriatic treatment they were given
chlorpromazine and the psoriatic lesions disappeared but the severe erythema of
the exposed areas remained; in contrast to other patients who did not have
chiorpromazine they maintained their erythema, and in other patients the cry-
thema from ultraviolet soon disappeared.
DR. JOHN H. EPSTEIN, (in closing): I would like to thank the discussors for
their remarks.
I was interested in Dr. Cahn's findings in Philadelphia on his patients clini-
cally. We too have had a few cases of photosensitivity due to chlorpromazine
(that is not induced by our experimental methods). I think he has isolated the
offending wave length bands even more than we have.
In answer to Doctor Rothman's question, the hot quartz does have a contin-
uous spectrum, though it is quite weak, which would suggest that we would have
to leave it on longer to burr' in wave lengths not included in the high intensity
bands. The hot quartz does have intense spectral lines in the sunburn spectrum
(2970 A, 3020 A, 3130 A).
Doctor Cornbleet mentioned that photosensitivity is not a common reaction.
I think that is true. However, dermatitis medicamentosa occurs in between 10
and 20 per cent of most series. We do see some patients who are severely troubled
with photosensitivity reactions and the small number of these reactions might
be related to the lack of sun exposure of people on relatively high doses of the
drug.
Doctor Stolar spoke of the persistence of erythema. That occurred in three of
our patients. We could not detect the tan until long after the time of the other
patients in our study. Phenargan may produce persistent photosensitivity for
several years and it is not inconceivable that this could also occur with chior-
promazine.
